GLP-1RAs have also been beneficial in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) (25)
Approval (2017) Compounding when drugs are on FDAs drug shortages list (August 08, 2025) FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize (April 28, 2025) FDAs concerns with unapproved GLP-1 drugs used for weight loss (September 05, 2025) Semaglutide: Double-edged Sword with Risks and Benefits (February 3, 2025)
Background: Dementia, Alzheimers & Type 3 Diabetes Dementiaespecially Alzheimers disease (AD)is a progressive decline in cognition, memory, planning, and daily functioning
Regional Leadership: North America dominates with 41% share, Europe follows with 28%, Asia-Pacific contributes 22%, Middle East & Africa hold 9%